Sales & Marketing News | pharmaphorum

News

Novo Nordisk shrugs off supply issues with record sales

Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt

News

GSK grabs early lead in RSV vaccine race with Pfizer

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the f

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita

News

FDA clears Roche’s Vabysmo for retinal vein occlusion

Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of th

News

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

After an earlier rejection, the FDA has approved Eli Lilly’s first-in-class IL-23p19 inhibitor mirikizumab as a treatment for adults with moderately to severely active ulc

Novo Nordisk shrugs off supply issues with record sales

GSK grabs early lead in RSV vaccine race with Pfizer

Imfinzi faces Keytruda competition in biliary tract cancer

Alfasigma to buy Galapagos’ JAK drug for up to €170m

FDA clears Roche’s Vabysmo for retinal vein occlusion

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks